Clinical Trials Sponsored by Qian-wei Li
Total 69 results
-
Qian-wei LiUnknown
-
Wei LiRecruitingCT Examination of the AbdomenChina
-
Dr Foo Li LianUnknown
-
Li Xiao WeiNot yet recruitingHepatocellular Carcinoma With PVTTChina
-
Hangzhou Wei Qiang Medical Technology Co., Ltd.CompletedPeripheral Vascular DiseasesChina
-
Lei LiRecruitingEpithelial Ovarian Cancer | Circulating Tumor DNA | CA125 | DNA Methylation | Non-invasive Diagnosis | Human Epididymis Protein 4 | Imaging Evaluation | Survival Prognosis | ROMA IndexChina
-
Lei LiRecruitingChemotherapy | Ovarian Carcinoma | Survival Outcomes | Adverse Events | Niraparib | Anlotinib | CA125 | Targeted Therapy | Recurrent Ovarian CancerChina
-
Lei LiRecruitingCervical Carcinoma | Immunotherapy | Survival Outcomes | Adverse Events | Locally Advanced Cervical Cancer | Chemoradiotherapy | Immune Checkpoint Inhibitor | Anti-programmed Cell Death Receptor 1 | Early Stage Cervical CancerChina
-
Lei LiRecruitingRecurrence | Survival Outcomes | Adjuvant Therapy | Hormone Therapy | Low Grade Endometrial Stromal Sarcoma of Uterus (Diagnosis) | Fertility-sparing Surgery | Fertility OutcomesChina
-
Lei LiRecruitingRecurrent Cervical Carcinoma | Radiotherapy | Immunotherapy | Survival Outcomes | Immune Checkpoint Inhibitors | Objective Response Rate | Metastatic Cervical Carcinoma | Tislelizumab | Persistent Cervical Carcinoma | Anti-programmed Cell Death Receptor 1China
-
Lei LiRecruitingChemotherapy | Recurrent Cervical Carcinoma | Immune Checkpoint Inhibitors | Anti-PD-1 Antibody | Persistent Advanced Cervical Carcinoma | Albumin-bound PaclitaxelChina
-
Lei LiRecruitingMicrosatellite Instability | Recurrent Cervical Cancer | PD-L1 | Nucleotide Variant | Copy Number Variation | Insertion-deletion Variation | Genomic Structural Variation | Total Mutation Burden | PD-1China
-
Lei LiRecruitingEndometrial Neoplasms | SurvivalChina
-
Lei LiUnknownEpithelial Ovarian Cancer | Homologous Recombination Deficiency | Prognosis | BRCA Mutation | Loss of Heterozygosity | Platinum ResistanceChina
-
Lei LiUnknownCervical Intraepithelial Neoplasia | Cervical Cancer Screening | Histology | p16 Protein | Cytology | High-risk Human Papillomavirus | Diagnostic AccuracyChina
-
Lei LiUnknownEpithelial Ovarian Cancer | Liquid Biopsy | DNA Methylation | Benign Ovarian Tumor | Training Set | Validation Set | Cell-free DNAChina
-
Lei LiUnknownCamrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine CarcinomasChemotherapy | Recurrent Cervical Carcinoma | Adverse Drug Event | Cervical Neuroendocrine Carcinoma | Objective Response Rate | Advanced Cervical Carcinoma | Anti-pd-1 AntibodyChina
-
Lei LiUnknownEpithelial Ovarian Cancer | BRCA1 Mutation | BRCA2 Mutation | Homologous Recombination Deficiency | Prognosis | ChineseChina
-
Lei LiUnknownEndometrial Cancer | Adenomyosis | Genomics | Eutopic Endometrium | Transcriptomics | Ectopic Endometrial TissueChina
-
Lei LiUnknownEpithelial Ovarian Cancer | Metabolomics | Transcriptomics | Whole Exome Sequencing | Tumor Invasiveness | TumorigenesisChina
-
Lei LiUnknown
-
Lei LiUnknownUterine Cervical Neoplasms | SurvivalChina
-
Lei LiRecruitingEpithelial Ovarian Cancer | Homologous Recombination Deficiency | Homologous Recombination Repair Gene Mutation | Drug Resistance | Overall Survival | Progression-free Survival | Poly(ADP-ribose) Polymerase InhibitorChina
-
Lei LiRecruitingCervical Cancer | Cervical Intraepithelial Neoplasia | Human Papillomavirus Infection | Cancer Screening | Cervical CytologyChina
-
Lei LiRecruitingQuality of Life | Mortality | Pelvic Floor Disorders | Laparotomy | Laparoscopy | Cost-Benefit Analysis | Morbidity | Survival | Uterine Cervical NeoplasmChina
-
Lei LiRecruitingRecurrence | Uterine Cervical Neoplasms | Mortality | Laparotomy | Laparoscopy | SurvivalChina
-
Lei LiCompletedChemotherapy | Recurrent Cervical Carcinoma | Immunotherapy | Anti-PD-1 Antibody | Persistent Advanced Cervical CarcinomaChina
-
Lei LiCompletedChemotherapy | Recurrent Cervical Carcinoma | Apatinib | Targeted Therapy | Persistent Advanced Cervical Carcinoma | Vascular Endothelial Growth Factor 2 InhibitorChina
-
Lei LiUnknownCervical Cancer | Cervical Intraepithelial Neoplasia | DNA Methylation | Cytology | High-risk Human PapillomavirusChina
-
Lei LiUnknownQuestionnaire | China | Workplace Violence Against Physicians | National Survey | Obstetrics and Gynecology | Random SampleChina
-
Lei LiUnknownPregnancy | Fertility | Precancerous Lesions | Human Papillomavirus Infection | Uterine Cervical Cancer | High Grade Intraepithelial Neoplasia | ConizationChina
-
Lei LiUnknownGynecologic Cancer | Febrile Neutropenia | Chemotherapy-induced Neutropenia | Myelosuppression AdultChina
-
Lei LiUnknownLynch Syndrome | Endometrial Cancer | Microsatellite Instability | Circulating Tumor CellChina
-
Lei LiUnknownEndometriosis | Adenomyosis | Genomics | Metabolomics | Ectopic Endometrium | Eutopic Endometrium | TranscriptomicsChina
-
Lei LiUnknownOvarian Cancer | High Grade Serous Carcinoma | Prognosis | Early Diagnosis | ExosomesChina
-
Lei LiRecruitingEpithelial Ovarian Cancer | Circulating Tumor DNA | CA125 | DNA Methylation | Non-invasive Diagnosis | Human Epididymis Protein 4 | Imaging Evaluation | Survival PrognosisChina
-
Lei LiRecruitingRecurrent Cervical Carcinoma | Radiotherapy | Immune Checkpoint Inhibitors | Overall Survival | Anti-programmed Death-1 Antibody | Metastatic Cervical Carcinoma | Persistent Advanced Cervical Carcinoma | Objective Remission Rate | Progression-free Survival | Severe Adverse EventsChina
-
Lei LiRecruitingRecurrent Ovarian Carcinoma | Platinum-resistant Ovarian Cancer | Bevacizumab | Ovarian Carcinoma | Survival Outcomes | Adverse Events | Albumin-bound PaclitaxelChina
-
Lei LiRecruitingChemotherapy | Recurrent Cervical Carcinoma | Survival Outcomes | Targeted Therapy | Adverse Effect | Metastatic Cervical Carcinoma | Persistent Advanced Cervical CarcinomaChina
-
Lei LiRecruitingEpithelial Ovarian Cancer | High-grade Serous Ovarian Carcinoma | Survival Outcomes | Overall Survival | Progression-free Survival | Chromosomal Instability | Somatic Copy Number Distortion | Minimal Residual LesionsChina
-
Lei LiRecruitingRecurrent Cervical Carcinoma | Radiotherapy | Objective Response Rate | Overall Survival | Progression-free Survival | Epidermal Growth Factor Receptor | NimotuzumabChina
-
Lei LiRecruitingEpithelial Ovarian Cancer | Microsatellite Instability | PD-L1 | Nucleotide Variant | Copy Number Variation | Insertion-deletion Variation | Genomic Structural Variation | Total Mutation Burden | PD-1China
-
Lei LiRecruitingQuality of Life | Cervical Cancer | Pelvic Floor Disorders | Survivorship | Overall Survival | Disease-free Survival | Urodynamics | Ovarian Reserve Function | Rectum Dynamics | Sex DysfunctionChina
-
Lei LiRecruitingLaparotomy | Laparoscopy | Locally Advanced Cervical Cancer | Neoadjuvant Chemotherapy | Adjuvant Therapy | Concurrent Chemoradiotherapy | Radical Hysterectomy | Objective Response | Systematic ChemotherapyChina
-
Lei LiRecruitingFebrile Neutropenia | Epithelial Ovarian Cancer | Adverse Event | Cost-effectiveness | Myelosuppression Adult | Colony Stimulating FactorsChina
-
Lei LiRecruitingColorectal Neoplasms, Hereditary Nonpolyposis | Hysterectomy | Hereditary Breast and Ovarian Cancer Syndrome | OvariectomyChina
-
Lei LiCompletedEpithelial Ovarian Cancer | BRCA1 Mutation | BRCA2 Mutation | Homologous Recombination Deficiency | Prognosis | Chinese | Homologous Recombination GenesChina
-
Lei LiUnknownEndometrial Cancer | Liquid Biopsy | DNA Methylation | Diagnostic Accuracy | Cervical Cytology | Training Set | Validation SetChina
-
Lei LiUnknownQuestionnaire | China | National Survey | Obstetrics and Gynecology | Workload | COVID-19 PandemicsChina
-
Lei LiUnknownDNA Methylation | Uterine Cervical Cancer | High Grade Squamous Intraepithelial Lesions | Low Grade Squamous Intraepithelial LesionsChina